Randomized, controlled trial of daily trimethoprim-sulfamethoxazole or weekly chl

每日甲氧苄啶-磺胺甲恶唑或每周一次 Chl 的随机对照试验

基本信息

  • 批准号:
    7511837
  • 负责人:
  • 金额:
    $ 21.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-08-01 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A daily regimen of the antibacterial drug trimethoprim-sulfamethoxazole (TS) reduces disease and death among people living with HIV in sub-Saharan Africa by preventing opportunistic infections including bacteremia, pneumonia and enteritis as well as malaria. It is not known whether this protective effect persists after immune reconstitution in HIV-infected persons receiving antiretroviral therapy (ART) or if infections prevented by TS, including malaria, influence the progression of HIV disease. With the scaling up of ART in Africa, public health authorities need to know if TS prophylaxis is necessary for those who are stable on ART. ART is associated with a dramatically reduced risk of typical AIDS-associated opportunistic infections. We therefore hypothesize that if there is a benefit of TS prophylaxis after immune reconstitution in this setting it will be due to the prevention of malaria infection, and that prophylaxis with a highly efficacious antimalarial drug (chloroquine, which now has 99% efficacy against malaria in Malawi) will be superior to daily prophylaxis with an antibacterial drug with lower antimalarial efficacy (TS, which had 80% efficacy against malaria in recent studies in Malawi). The overall public health objective of this application is to determine if TS can safely be stopped after immune reconstitution on ART. The primary research question is whether persons who are clinically stable on ART benefit from antibacterial prophylaxis, antimalarial prophylaxis, both, or neither. Secondary questions focus on understanding the role that antimicrobial prophylaxis may play in improving sustained responses to ART by preventing infections associated with rises in HIV viral load, and assessing antimalarial drug efficacy and selection for drug resistance in HIV-infected persons. To address these questions, we have designed a three-arm randomized open-label clinical trial comparing daily TS prophylaxis for prevention of malaria and bacterial infections, with weekly chloroquine prophylaxis to prevent only malaria, compared to no prophylaxis, in adults who are clinically stable after 6-12 months on ART. Under previous funding a protocol for this trial has been written and IRB approval obtained. This R34 will support completion of planning for the study and lead to submission of a U01 grant application to support the conduct of the clinical trial at the Blantyre Malaria Project Ndirande Research Clinic in Blantyre, Malawi.
描述(由申请人提供):抗菌药物甲氧苄啶-磺胺甲恶唑(TS)的每日方案通过预防机会性感染(包括菌血症、肺炎和肠炎以及疟疾),减少撒哈拉以南非洲艾滋病毒感染者的疾病和死亡。目前尚不清楚这种保护作用是否在接受抗逆转录病毒治疗(ART)的HIV感染者免疫重建后持续存在,或者TS预防的感染(包括疟疾)是否会影响HIV疾病的进展。随着抗逆转录病毒疗法在非洲的推广,公共卫生当局需要知道,对于那些稳定接受抗逆转录病毒疗法的人,TS预防是否有必要。因此,我们假设,如果在这种情况下免疫重建后TS预防有益处,那将是由于预防疟疾感染,并且使用高效抗疟药物预防(氯喹,目前在马拉维对疟疾有99%的疗效)将上级抗疟疗效较低的抗菌药物每日预防(TS,在马拉维最近的研究中对疟疾有80%的疗效)。 本申请的总体公共卫生目标是确定TS在ART免疫重建后是否可以安全地停止。主要研究问题是ART临床稳定的人是否受益于抗菌预防、抗疟预防或两者兼而有之。次要问题集中在了解抗菌预防在通过预防与HIV病毒载量上升相关的感染来改善对ART的持续反应方面可能发挥的作用,以及评估抗疟药物的疗效和HIV感染者的耐药性选择。为了解决这些问题,我们设计了一项三臂随机开放标签临床试验,在接受ART治疗6-12个月后临床稳定的成人中比较每日TS预防预防疟疾和细菌感染,每周氯喹预防仅预防疟疾。 根据先前的资助,已经编写了本试验的方案,并获得了IRB的批准。该R34将支持完成研究计划,并导致提交U 01资助申请,以支持在马拉维布兰太尔的布兰太尔疟疾项目Ndirande研究诊所开展临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER V. PLOWE其他文献

CHRISTOPHER V. PLOWE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER V. PLOWE', 18)}}的其他基金

Ultra-dense peptide array analysis of naturally acquired and vaccine-induced P. falciparum immunity
自然获得性和疫苗诱导的恶性疟原虫免疫的超密集肽阵列分析
  • 批准号:
    9182505
  • 财政年份:
    2016
  • 资助金额:
    $ 21.65万
  • 项目类别:
Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adults
PfSPZ 疟疾疫苗对疟疾暴露成人的安全性和有效性
  • 批准号:
    8989966
  • 财政年份:
    2015
  • 资助金额:
    $ 21.65万
  • 项目类别:
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigen
血期疟疾疫苗抗原的免疫流行病学表位作图
  • 批准号:
    8234592
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Pilot studies of the molecular epidemiology of drug-resistant malaria in Myanmar
缅甸耐药疟疾分子流行病学试点研究
  • 批准号:
    8583301
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigen
血期疟疾疫苗抗原的免疫流行病学表位作图
  • 批准号:
    8607885
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Pilot studies of the molecular epidemiology of drug-resistant malaria in Myanmar
缅甸耐药疟疾分子流行病学试点研究
  • 批准号:
    8356232
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigen
血期疟疾疫苗抗原的免疫流行病学表位作图
  • 批准号:
    8795656
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Immuno-epidemiological epitope mapping of a blood stage malaria vaccine antigen
血期疟疾疫苗抗原的免疫流行病学表位作图
  • 批准号:
    8416955
  • 财政年份:
    2012
  • 资助金额:
    $ 21.65万
  • 项目类别:
Malaria Vaccine Trials in Mali
马里的疟疾疫苗试验
  • 批准号:
    6960293
  • 财政年份:
    2005
  • 资助金额:
    $ 21.65万
  • 项目类别:
Genetic diversity and protective immunity to malaria infection and disease
遗传多样性和对疟疾感染和疾病的保护性免疫力
  • 批准号:
    8291906
  • 财政年份:
    2005
  • 资助金额:
    $ 21.65万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.65万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了